Mesoblast Ltd (MESO) Gets a Buy Rating from Oppenheimer


In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Mesoblast Ltd (MESO). The company’s shares opened today at $4.99.

According to TipRanks.com, Breidenbach is a 3-star analyst with an average return of 2.0% and a 40.9% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Alpine Immune Sciences Inc, and Global Blood Therapeutics.

Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $14.19.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.78 and a one-year low of $3.35. Currently, Mesoblast Ltd has an average volume of 52.18K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts